Metabolic impact of growth hormone treatment in short children born small for gestational age.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Growth hormone (GH) treatment in short children born small for gestational age (SGA) may result in metabolic changes with potential long-term effects.

Who Took Part

The study group was 149 children.

By PubMed's age tags, the people studied were young children and children, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Leptin, ghrelin, insulin-like growth factor-I (IGF-I), IGF binding protein-1 (IGFBP-1), lipids, fasting blood glucose and fasting insulin were assessed at baseline, 12 and 24 months.

What Was Measured

PubMed files the paper under topics including Body Height, Ghrelin, Human Growth Hormone, Infant, Small for Gestational Age, Insulin, Insulin-Like Growth Factor Binding Protein 1 and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 149 children.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2011 (Hormone research in paediatrics), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.